Roche
Pays vs peer median
×1.36
+36% premium
Sample
40
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.00 | 15 |
| immunology | ×1.50 | 8 |
| metabolic | ×1.50 | 5 |
| neurology | ×0.90 | 3 |
| cardiovascular | ×1.06 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 2 | ×1.50 | 14 |
| preclinical | ×0.83 | 9 |
| phase 1 | ×1.20 | 8 |
| phase 3 | ×1.20 | 6 |
| approved | ×1.50 | 3 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | — | SangeneBio | — | discovery | $200M | $1.7B |
| 2026 | Anti-CD47-001 | Affimed | HCC | phase_1 | $64M | $406M |
| 2025 | ICOS-101 | Ono Pharmaceutical | Pancreatic | phase_3 | $1.0B | $6.2B |
| 2025 | KIT-mab | Syros Pharmaceuticals | Cholangiocarcinoma | phase_2 | $385M | $2.4B |
| 2025 | HER2 | MorphoSys | Cholangiocarcinoma | phase_2 | $263M | $2.2B |
| 2025 | MET-101 | Nkarta | RCC | discovery | $6M | $119M |
| 2025 | FGFR-201 | Zai Lab | Breast (HER2+) | preclinical | $50M | $760M |
| 2025 | Pegozafermin (MASH acquisition) | 89bio | MASH with fibrosis, MASH cirrhosis | phase_3 | $2.4B | $3.5B |
| 2025 | KRAS G12C-mab | Astellas | Breast (HR+) | phase_2 | — | $790M |
| 2025 | WEE1 | RemeGen | Ovarian | phase_2 | $269M | $1.7B |
| 2025 | HER2 | Alphamab Oncology | Head & Neck | phase_2 | $251M | $2.7B |
| 2025 | Anti-MEK | Junshi Biosciences | CLL | phase_1 | $105M | $884M |
| 2025 | Anti-LRRK2-nib | Passage Bio | Parkinson's Disease | approved | $478M | $1.6B |
| 2025 | MET | Relay Therapeutics | NSCLC | approved | $3.8B | $19.7B |
| 2025 | B7-H3 | Kelun-Biotech | Colorectal | preclinical | — | $1.2B |
How this is computed
For each Roche deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 40 disclosed deal premiums vs. peer medians. Raw premium 1.363, clamped to [0.7, 1.5].